

To: UCM and Ingalls Medical Staff, House staff, Nursing Staff, Patient Care Centers, and Outpatient Clinics

From: Vishnu Samara, PhD
Assistant Professor and Assistant Director, Clinical Chemistry

Date: 9/30/2025

Subject: Hepatitis B Virus (HBV) Surface Antibody Assay Update at UCM Hyde Park Clinical Chemistry Lab

Effective Date: 10/2/2025

Laboratory Section: Chemistry

Summary:

Effective October 2, 2025, the Hyde Park Clinical Chemistry Laboratory will transition to an updated Hepatitis B Virus Surface Antibody assay (Roche Elecsys Anti-HBs II), which is significantly less susceptible to biotin interference (showing no interference at biotin concentrations up to 1200 ng/mL) compared to the current assay.

This updated assay also changes the criterion for immunity to HBV, as indicated in the table below, with the elimination of the indeterminate category. Results will be reported only as Reactive or Non-reactive.

Elecsys Anti-HBs II result (not displayed in EPIC)	Result interpretation (shown in EPIC)	Clinical interpretation of HBV immune status
< 10 mIU/mL	Non-reactive	Individual is considered to be <i>not immune</i> to infection with HBV.
≥ 10 mIU/mL	Reactive	Individual is considered to be <i>immune</i> to infection with HBV

The test name and test code will remain the same:

Test Name: HEPATITIS B SURFACE ANTIBODY

Test Code: HBSAB

Questions:

If there are any questions regarding this change, please contact:

- Vishnu Samara, PhD, Assistant Medical Director, Clinical Chemistry Service vsamara@bsd.uchicago.edu
- Clarence Chan, MD, PhD, Assistant Medical Director, Clinical Chemistry Service clarence.chan@bsd.uchicago.edu